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Anaphylactoid reactions during hemodialysis in sheep are ACE inhib-
itor dose-dependent and mediated by bradykinin. Anaphylactoid reac-
tions (AR) have been attributed to the generation of bradykinin (BK)
when AN69 membranes are used together with angiotensin converting
enzyme (ACE) inhibitors during hemodialysis. However, conclusive evi-
dence for the involvement of the BK as the mediator of these AR is still
lacking. This study examined the degree of contact activation in an animal
model caused by three PAN membranes—AN69, PAN DX, and SPAN—
and the effects of different doses of the ACE inhibitor enalapril (ENA)
and the BK B2-receptor antagonist icatibant on AR during hemodialysis.
Six sheep were dialyzed for one hour with or without ENA pre-treatment
using the different membranes in random order. Severe AR were ob-
served only during hemodialysis with AN69 dialyzers together with ENA
pre-treatment; the severity of AR increased with the ENA dose. Mild
hypotension was noted during hemodialysis with AN69 without ACE
inhibition and with PAN DX and 20 mg ENA. Compared to pre-dialysis
values, maximum generation of BK after blood passage through the
dialyzer was found at five minutes: 73-fold (AN69 without ENA), 161-fold
(AN69 with 10 mg ENA), 97-fold (AN69 with 20 mg ENA), 108-fold
(AN69 with 30 mg ENA), 154-fold (AN69 with 30 mg ENA and 0.1 mg/kg
icatibant), 18-fold (PAN DX without ENA), and 42-fold (PAN DX with
20 mg ENA). Elevated BK levels in arterial blood were detected during
hemodialysis with AN69 membranes even without ACE inhibition (2.5-
fold); pre-treatment with 20 mg ENA further increased arterial BK
concentrations (4-fold). Furthermore, a marked decline of prekallikrein
and high molecular weight kininogen concentrations was noted for both
AN69 and PAN DX membranes. Anaphylactoid reactions during hemo-
dialysis were completely prevented by icatibant even after pre-treatment
with ENA and in the presence of high BK concentrations. Concentrations
of prekallikrein, high molecular weight kininogen, and BK remained
unchanged and no AR were observed during hemodialysis with SPAN and
pre-treatment with 20 mg ENA. Our findings confirm that AR during
hemodialysis with the negatively charged AN69 membrane are mediated
by BK, since they can be prevented by the BK B2-receptor antagonist
icatibant.
Anaphylactoid reactions during hemodialysis with high-flux
polyacrylonitrile (AN69) dialyzers in patients receiving angioten-
sin converting enzyme (ACE) inhibitors were first observed in
1990 [1, 2]. Since then, about 50 cases have been reported [3–7].
Apart from a possible involvement of bacterial endotoxins, con-
tact activation initiating bradykinin generation together with a
reduction of kininase II (5 ACE; the key enzyme involved in kinin
degradation) activity resulting from pre-treatment with ACE
inhibitors have been implicated as pathogenetic factors in these
reactions [1, 2]. Evidence supporting the role of bradykinin in
anaphylactoid reactions has come from in vitro and in vivo studies
showing that incubation of AN69 membranes with human plasma
led to bradykinin generation [8, 9]. A dose-dependent addition of
an ACE inhibitor resulted in a further increase and stability of
bradykinin levels [8, 9]. The association of AN69 membrane usage
and bradykinin release in blood after passage through the dialyzer
was confirmed in an animal study with sheep; pre-treatment with
the ACE inhibitor captopril resulted in even higher bradykinin
levels and severe anaphylactoid reactions [10]. These findings
were in accordance with clinical data of patients treated with ACE
inhibitors showing high bradykinin levels at the onset of anaphy-
lactoid reactions during hemodialysis with AN69 dialyzers [11].
To date, confirmatory evidence of the involvement of bradyki-
nin as the mediator of these anaphylactoid reactions is still
lacking. The present study was performed to investigate the extent
of contact activation induced by three different polyacrylonitrile
membranes—AN69, PAN DX, and SPAN—and their ability to
evoke anaphylactoid reactions in an animal model. To add further
proof to the “bradykinin hypothesis,” we wished to examine the
effects of different ACE inhibitor doses and the effects of the
selective bradykinin B2-receptor antagonist icatibant (Hoe 140)
on anaphylactoid reactions and bradykinin generation during
hemodialysis with the AN69 membrane.
METHODS
Animal model
An animal model using sheep was chosen for the studies. Sheep
are very suitable for hemodialysis experiments since their body
mass and blood circulation parameters are comparable to that of
humans, as well as providing good vascular access [10].
Six female blackhead sheep, weighing between 51.4 and 99.4 kg,
were hemodialyzed in a random order. Vascular access was
achieved with a double lumen hemodialysis catheter inserted into
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a jugular vein. A blood flow rate of 200 ml/min was selected.
Acetate dialysate (concentrate HDY 76®, calcium concentration
1.75 mmol/liter; B. Braun Melsungen AG, Germany) and a Braun
hemodialysis machine (HD Secura®) was used. Hemodialysis was
carried out for 60 minutes with an ultrafiltration rate of 500 ml/hr.
For anticoagulation, heparin was given at a constant infusion rate
of 1000 units/hr following an initial bolus dose of 5000 units. No
clotting was observed in the extracorporeal circuit in any of the
experiments. To avoid hypotension the priming fluid within the
extracorporeal circuit (400 ml) was administered to the sheep at
the start of dialysis. About four hours after the completion of the
experiments the hemodialysis catheters were removed to prevent
dislocation or infectious complications. Each sheep was dialyzed
with the AN69 membrane (membrane surface area 1.6 m2;
Filtral®, Hospal, Germany), the PAN DX membrane (membrane
surface area 1.7 m2; PAN-85DX®; Asahi Medical, Germany), and
the SPAN membrane (membrane surface area 1.8 m2; Akzo
Nobel Faser AG, Germany) with and without ACE inhibition.
The intervals between the experiments were at least three days.
Angiotensin converting enzyme inhibition
For ACE inhibition enalapril (Xanef®; MSD, Germany) was
given daily in two equal doses by oral application starting one
week before dialysis. On the day of the experiment enalapril was
given 30 minutes before beginning dialysis.
Bradykinin B2-receptor antagonist
Icatibant (Hoe 140) is known to be a potent and long-acting
bradykinin B2-receptor antagonist, and efficient in various in vivo
studies [12]. Recently, it has been shown to prevent anaphylactoid
reactions in human low density lipoprotein (LDL) apheresis
under ACE inhibition when given prior to the treatment [13]. In
the present study icatibant was administered in one defined group
of sheep by slow intravenous infusion of 0.1 mg/kg body wt five
minutes before dialysis.
Test protocol and analytical methods
Eight experimental groups differing with regard to dialyzer
type, enalapril dose, and bradykinin B2-receptor antagonist were
defined. In each group all six animals were tested as follows:
(1) group AN/0 (N 5 6), AN69 without ACE inhibition;
(2) group AN/10 (N 5 6), AN69 with 10 mg/day enalapril;
(3) group AN/20 (N 5 6), AN69 with 20 mg/day enalapril;
(4) group AN/30 (N 5 6), AN69 with 30 mg/day enalapril;
(5) group AN/BA (N 5 6), AN69 with 30 mg/day enalapril and
0.1 mg/kg bradykinin B2-receptor antagonist icatibant (Hoe
140);
(6) group PA/0 (N 5 6), PAN DX without enalapril;
(7) group PA/20 (N 5 6), PAN DX with 20 mg/day enalapril;
(8) group SP/20 (N 5 6), SPAN with 20 mg/day enalapril
(control goup).
To investigate the extent of contact activation, the concentra-
tions of bradykinin, prekallikrein and high molecular weight
kininogen were determined.
After dialysis was started, samples for the determination of
bradykinin were drawn from blood entering and leaving the
dialyzer at 0, 5, 15, and 60 minutes. In addition, for two animals in
groups AN/0 and AN/20, blood samples were also taken from a
catheter inserted into a carotid artery prior to the experiment. The
samples were collected and processed according to the method of
Shimamoto et al [14]. The radioimmunoassay of kinin was per-
formed as described previously [15].
Blood samples for prekallikrein and high molecular weight
kininogen determination were taken at 0, 15, and 60 minutes from
venous blood. Preparation of the samples and measurement of
prekallikrein was performed as described by Boenner et al [16].
Uncleaved high molecular weight kininogen was measured by a
method similar to that described by Uchida and Katoni [17].
For the determination of ACE activity, samples were collected
immediately before the start of dialysis. Assays were carried out
on plasma by measuring angiotensin II generation using a com-
mercially available test (Hycor Biomedical Inc., Irvine, Ca, USA).
To assess a possible role of histamine in the anaphylactoid
reactions, plasma histamine was determined before and 15 min-
utes after the beginning of hemodialysis using an enzyme immu-
noassay (Immunotech, AMAC Inc., USA).
Before and after the experimental procedures blood samples
for the determination of hemoglobin, platelet count, white blood
cells, total serum protein, and activated partial thromboplastin
time (APTT) were also drawn.
Registration of anaphylactoid reactions
To identify hypotensive episodes during the experiments blood
pressures and heart rates were recorded at one minute intervals by
an automatic device (Critikon “dynamap” 1846 SX, USA) using a
“tail cuff” (neonatal cuff No. 4). This non-invasive method for
blood pressure monitoring in sheep has been proven in a previous
study to deliver reliable data compared to intra-arterial measure-
ments [10]. The ventilation rate was obtained by counting breaths/
min and recorded every five minutes. Furthermore, the animals
were observed continuously with regard to symptoms of anaphy-
lactoid reaction like circulatory collapse and edema.
Statistical analysis
Results are expressed as mean values 6 SD. Wilcoxon’s matched
pairs signed rank test was used to compare data within each
group. Differences were considered significant at P , 0.05.
RESULTS
Appearance of anaphylactoid reactions
Clinically overt anaphylactoid reactions could be observed only
in groups AN/10, AN/20, and AN/30. The symptoms began after
five minutes of dialysis and included hypotension leading to
restlessness, unsteady standing, and collapsed in the worst case.
Furthermore, the sheep showed respiratory problems in the form
of prolonged tachypnoea. Edema of the face was not observed.
The symptoms were similar in these three groups but differed in
frequency and severity. The afflicted animals recovered within 5 to
10 minutes without having obtained any particular treatment like
fluid application, etc.
The mildest anaphylactoid reactions could be observed in group
AN/10. In this group only one sheep collapsed while three animals
showed no symptoms at all. There was a statistically significant fall
of systolic blood pressure from 108 6 7.5 to 72 6 14.2 mm Hg
linked to a significant rise of heart rate from 100 6 18.7 to 149 6
24.1 beats/min after five minutes, followed by a continuous
recovery of the hemodynamic situation in the further course of
dialysis, without changing the treatment mode or application of
fluid (Fig. 1B). The ventilation rate in group AN/10 remained
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Fig. 1. Systolic blood pressure (l) and heart rate (u) during 60 minutes of hemodialysis. Data are mean values 6 SD of six sheep. (A) Group AN/0;
(B) group AN/10; (C) group AN/20; (D) group AN/30; (E) group AN/BA; (F) group PA/0; (G) group PA/20; (H) group SP/20. *P , 0.05 versus 0
minutes, **P , 0.05 versus 25 minutes.
elevated and almost unchanged during the first 15 minutes of
dialysis but fell significantly at 30 minutes (Fig. 2).
In group AN/20 all animals except one showed symptoms: one
animal collapsed and the other four had minor signs of anaphy-
lactoid reaction. After five minutes of treatment, a considerable
and significant hypotension was observed, with systolic blood
pressure falling from 109 6 7.7 to 55 6 13.4 mm Hg, and the heart
rate increased from 99 6 9.6 to 135 6 14.1 beats/min. Until 40
minutes of treatment time the systolic blood pressure was signif-
icantly lower compared to the beginning of dialysis (Fig. 1C). The
ventilation rate rose significantly with a maximum after 10 min-
utes (127 6 17 vs. 157 6 27 breaths/min) and normalized
gradually after 30 minutes (Fig. 2).
The most severe anaphylactoid reactions could be noted in
group AN/30. All six sheep showed severe symptoms, three
animals in the form of collapse. There was a significant drop of
systolic blood pressure from 100 6 5.6 mm Hg before dialysis, to
54 6 12.8 after five minutes reaching a minimum of 53 6 7.5 mm
Hg after 10 minutes of experiment indicating a pronounced state
of shock (Fig. 1D). Simultaneously, the heart rate increased
significantly from 108 6 16 to a maximum of 150 6 20.3 beats/min
after five minutes. After 30 minutes of dialysis, blood pressure and
heart rate had stabilized without the necessity of interrupting the
treatment or application of fluid to the animal. As in group
AN/20, the animals of group AN/30 had the maximal ventilation
rate after 10 minutes. This increase was not significant compared
to the pre-dialysis value (132 6 11 vs. 140 6 29 breaths/min; Fig.
2).
Immediately after application of the bradykinin receptor antag-
onist (before the start of dialysis) all animals in group AN/BA
(AN69 with 30 mg enalapril and icatibant) demonstrated adverse
effects: the symptoms were loss of urine and feces, regurgitation,
signs of abdominal discomfort, and hypersalivation that lasted for
hours after dialysis. However, it is interesting to note that none of
the animals showed symptoms of anaphylactoid reaction during
hemodialysis unlike that observed for sheep in groups AN/10 to
30. Furthermore, five minutes after application of icatibant, which
was at the beginning of dialysis, a significant rise of systolic blood
pressure from 101 6 7.2 to 127 6 15.9 mm Hg and an increased
heart rate (91 6 14.9 to 107 6 19.4 beats/min) could be observed,
but during the whole dialysis time (even in the first 10 min of the
experiment) the blood pressure and heart rate remained nearly
unchanged (Fig. 1E). Five minutes after the application of
icatibant a significant decrease of ventilation rate from 125 6 43
to 75 6 26 breaths/min at the beginning of dialysis was observed.
During the experiment the ventilation rate fell gradually (Fig. 2).
In all other groups (AN/0, PA/0, PA/20, SP/20) any form of
symptoms indicative of anaphylactoid reactions were absent.
In groups AN/0 and PA/20 blood pressure and heart rate took
an identical course during dialysis. Although there was no real
hypotension, a slight but significant decrease of systolic blood
pressure from 107 6 8.5 to 94 6 4.9 mm Hg in group AN/0 and
108 6 6.3 to 96 6 5.6 mm Hg in group PA/20, together with an
increase in heart rate (101 6 14.4 to 127 6 18.9 and 104 6 12.2
to 117 6 24.3 beats/min, respectively) could be noted after five
minutes (Fig. 1A and 1G). The circulation parameters were
normalized in both groups after 15 minutes of treatment.
In group PA/0, a minor reduction of systolic blood pressure
from 104 6 7.4 to 98 6 9 mm Hg established after five minutes.
This significant decline in blood pressure was not linked to an
increase of the heart rate like in the groups already mentioned
Fig. 2. Ventilation rate of all groups during 60 minutes of hemodialysis. Data are mean values of six sheep. *P , 0.05 versus 0 minutes; **P , 0.05
versus 15 minutes; ***P , 0.05 versus prior to icatibant application.
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(Fig. 1F). Thereafter, hemodynamic parameters remained incon-
spicuous throughout the course of the experiment.
Blood pressure and heart rate of the animals of group SP/20 did
not show any significant changes during the whole treatment
period (Fig. 1H).
In groups AN/0, PA/0, PA/20, and SP/20 the ventilation rates
were comparable and decreased continuously during the experi-
ment (Fig. 2).
Angiotensin converting enzyme inhibition
Figure 3 shows the ACE activity of all groups prior to the
experiments. The mean values of the groups without ACE inhi-
bition, groups AN/0 and PA/0, were 57.26 6 8.26 and 56.22 6
12.29 nmol/ml/min, respectively. Compared to groups AN/0 and
PA/0, a significantly lower ACE activity of 19.22 6 4.06 nmol/ml/
min could be detected in group AN/10. The ACE activity of group
AN/20 was 14.38 6 3.57 nmol/ml/min and differed significantly to
group AN/10. The values of group PA/20 and SP/20 (16.38 6 4.43
and 13.6 6 3.15 nmol/ml/min, respectively) were similar to group
AN/20 but significantly lower only compared to the groups
without ACE inhibition (AN/0 and PA/0). After 30 mg/day of
enalapril, groups AN/30 and AN/BA, the ACE activities
amounted to 11.60 6 5.26 and 10.99 6 2.99 nmol/ml/min,
respectively, and differed significantly to group AN/20.
Contact activation
Results of bradykinin determination before and after passage of
blood through the dialyzer are given in Figure 4. Most remarkable
was an intense and uniform generation of bradykinin after passage
of blood through the dialyzer in the groups in which the AN69
membrane was used, reaching its maximum after only five minutes
of dialysis. Fifteen and 60 minutes after the beginning of the
treatment, the bradykinin concentrations decereased slowly but
still remained significantly elevated compared to the pre-dialysis
values. The five minutes bradykinin concentrations after passage
through the dialyzer were increased 73-fold in group AN/0,
161-fold in group AN/10, 97-fold in group AN/20, 108-fold in
group AN/30, and 154-fold in group AN/BA. In these five groups
the kinetics of bradykinin levels in the blood samples drawn
before passage of the dialyzer were somewhat different: the
Fig. 3. Angiotensin converting enzyme (ACE)
activity of all groups before hemodialysis. Data
are mean values 6 SD of six sheep. *P , 0.05
versus group AN/0 and PA/0 (without ACE
inhibition); **P , 0.05 versus group AN/10;
***P , 0.05 versus group AN/20.
Fig. 4. Bradykinin concentrations of all groups before (front columns) and after (rear columns) passage through the dialyzer during 60 minutes of
hemodialysis. Data are mean values of six sheep. *P , 0.05 versus 0 minutes.
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highest bradykinin concentrations were measured at 15 minutes
after the start of experiment and rose to 10-fold in group AN/0,
14-fold in group AN/10, 9-fold in group AN/20, 17-fold in group
AN/30, and 20-fold in group AN/BA compared to the pre-dialysis
values. All bradykinin concentrations detected before passage of
the dialyzer at 5, 15, and 60 minutes were significantly different
from the initial values (0 min). As expected, the highest bradyki-
nin levels, that is, 15 minutes pre-dialyzer and five minutes
post-dialyzer, had been measured in group AN/30 and the lowest
in group AN/0 whereas the bradykinin concentrations in group
AN/10 and group AN/20 were not ACE inhibitor dose-dependent.
In group AN/10 the bradykinin concentrations were markedly
higher compared to group AN/20. Thus, there was no correlation
between the dose of ACE inhibitor and the amount of bradykinin
generation before or after passage of blood through the dialyzer.
Compared to group AN/0, the bradykinin levels at 5 and 15
minutes of treatment after the dialyzer in groups AN/10, AN/20,
AN/30 and AN/BA were significantly different.
To demonstrate the influence of ACE inhibition on arterial
bradykinin concentrations during hemodialysis with the AN69
membrane, additional arterial blood samples were drawn in
groups AN/0 and AN/20. In both groups the maximum levels were
reached at five minutes meaning a 2.5-fold increase in group AN/0
and a fourfold increase in group AN/20 (Fig. 5). Fifteen minutes
after beginning of dialysis, the bradykinin concentrations were still
markedly elevated and at 60 minutes the values were comparable
to 0 minutes (Fig. 5).
Hemodialysis with the PAN DX membrane was also associated
with a bradykinin release although not to the same extent as
AN69. In group PA/0 and PA/20 a significant 18-fold and 42-fold
increase, respectively, of bradykinin concentrations after passage
through the dialyzer could be observed five minutes after the start
of dialysis (Fig. 4). The difference in bradykinin generation
between groups PA/0 and PA/20 at five minutes was significant. A
significant elevation of bradykinin levels after passage of the
dialyzer was also detectable at 15 minutes in group PA/20. Before
passing the dialyzer bradykinin levels were not clearly different at
any time in both groups (Fig. 4).
The SPAN membrane did not lead to significant changes in
bradykinin concentrations, either before or after, passage of blood
through the dialyzer (Fig. 4).
To show the extent of contact activation, the plasma levels of
prekallikrein and HMW kininogen were determined.
A significant decrease of prekallikrein concentrations could be
observed in all groups except group SP/20 where no significant
changes could be demonstrated. Fifteen minutes after the begin-
ning of dialysis, this reduction in prekallikrein concentration was
13.4% in group AN/0, 13.8% in group AN/10, 8% in group AN/20,
29.1% in group AN/30, and 30.6% in group PA/0 (Fig. 6). In these
groups, the prekallikrein levels at 60 minutes were similiar to the
15 minute levels, and were significantly lower compared to the
pre-dialysis values (Fig. 6).
The fall of high molecular weight kininogen levels was even
more pronounced and detectable in groups AN/0 to 30 and PA/0.
In group SP/20 the high molecular weight kininogens levels did
not differ significantly in the course of dialysis (Fig. 7). After 15
minutes of treatment the significant reduction of high molecular
weight kininogen was 47% in group AN/0, 42% in group AN/10,
46% in group AN/20, 42% in group AN/30, and 25% in group
PA/0. At 60 minutes high molecular weight kininogen concentra-
tions were only slightly decreased in these groups (Fig. 7).
Further parameters
The evaluation of plasma histamine levels, total protein, and
white blood cells yielded no changes during the experiments (data
not shown).
The mean values of hemoglobin concentrations 6 SD before
dialysis were between 9.7 6 1.0 and 10.9 6 1.4 g/dl. At the end of
dialysis the concentrations were diminished in all groups to values
between 9.3 6 0.8 and 9.6 6 0.6 g/dl (not significant).
The platelet count took a similar course. Before dialysis platelet
counts between 320 6 108 and 393 6 87 3 103/ml were measured,
while at 60 minutes the mean values 6 SD were reduced to 270 6
103 and 318 6 135 3 103/ml. These differences were not signifi-
cant in all groups.
The mean values 6 SD of activated thromboplastin time
(APTT) of the groups before experiment were between 25 6 5
and 45 6 34 seconds. After an initial dose of 5000 IU heparin and
a continuous rate of 1000 IU/hr, the increment of APTT at 60
minutes was significant in all groups (176 6 155 to 370 6 170
seconds). No significant clotting problems occurred.
DISCUSSION
The bradykinin hypothesis
Recent studies have demonstrated the possible key role of
bradykinin in anaphylactoid reactions during hemodialysis with
the AN69 membrane in patients on ACE inhibitors [8–11].
However, definitive evidence that bradykinin is the mediator of
the observed anaphylactoid reactions has been lacking, causing
much controversy. Such evidence would be convincing when an
inhibitor of the postulated mediator could abolish the symptoms
of anaphylactoid reaction.
AN69 membranes are capable of generating bradykinin when
incubated with human blood [8, 9, 18]. This property may be
related to the negative charge of the membrane surface that
causes generation of active plasma kallikrein via contact activation
[9, 19, 20]. Plasma kallikrein, in turn, cleaves high molecular
weight kininogen under release of bradykinin. In the presence of
the inhibitors of ACE (5 kininase II), the major enzyme of kinin
Fig. 5. Bradykinin concentrations in plasma samples obtained from the
carotid artery of group AN/0 (AN69 without ACE inhibition; l) and
group AN/20 (AN69 with 20 mg enalapril; M) during 60 minutes of
hemodialysis. Data are mean values 6 SD.
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inactivation in vivo [21], bradykinin, passes the pulmonary circu-
lation without being inactivated and accumulates to high concen-
trations that are able to evoke anaphylactoid reactions [8]. This
“bradykinin hypothesis” was supported by several in vivo studies.
Recently, we have shown in an animal model that hemodialysis
with the AN69 membrane is associated with a bradykinin release
in blood after passage through the dialyzer [10]. Pre-treatment
with the ACE inhibitor captopril led to further increases in
bradykinin levels and resulted in anaphylactoid reactions [10].
Verresen et al demonstrated elevated bradykinin concentrations
in blood from the arterial line of the extracorporeal circuit in nine
patients under ACE inhibition suffering from anaphylactoid re-
actions during hemodialysis with AN69 dialyzers [11]. Although
the “bradykinin hypothesis” is backed by some experiments by
several groups, a number of issues remain unclear. Firstly, there
are a number of case reports about patients not experiencing
anaphylactoid reactions despite usage of AN69 dialyzers together
with pre-treatment with ACE inhibitors [22–26]. Such observa-
tions have led to the discussion about the varying individual
susceptibility for anaphylactoid reactions and a possible incom-
plete inhibition of kininase II due to a low dosage of ACE
inhibitors [9]. On the other hand, there is information about at
least four cases of severe anaphylactoid reactions and dialysis with
AN69 dialyzers without previous intake of ACE inhibitors [11, 25,
27]. In two of these patients excessive concentrations of bradyki-
nin were detected in the venous effluent of the dialyzers during
these episodes, strongly suggesting bradykinin as the mediator of
the observed reactions [11, 27]. The reason for the inability of
these patients to degrade bradykinin without present ACE inhib-
itor medication is not known.
Bradykinin as the mediator of anaphylactoid reactions
The results of our animal study further support the key role of
bradykinin in the pathogenesis of anaphylactoid reactions during
hemodialysis with the AN69 membrane and pre-treatment with
ACE inhibitors. Confirming other clinical, animal, and in vitro
Fig. 6. Prekallikrein concentrations of groups
AN/0, AN/10, AN/20, AN/30, PA/0, and SP/20
during 60 minutes of hemodialysis. Data are
mean values 6 SD of six sheep. Symbols are:
(f) 0 min; (s) 15 min; (1) 60 min. *P , 0.05
versus 0 minutes.
Fig. 7. High molecular weight kininogen
concentrations of groups AN/0, AN/10, AN/20,
AN/30, PA/0, and SP/20 during 60 minutes of
hemodialysis. Symbols are: (f) 0 min; (s) 15
min; (1) 60 min. Data are mean values 6 SD
of six sheep. *P , 0.05 versus 0 minutes.
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studies [9–11, 28], we show that hemodialysis with AN69 is
associated with an excessive generation of bradykinin with a peak
after five minutes of treatment in the venous effluent of the
dialyzer, with or without ACE inhibitor.
Elevated bradykinin levels were also found at the dialyzer inlet.
Probably due to systemic accumulation but possibly because
coating of the membrane by proteins may already have reduced
the ability of the AN69 membrane to generate bradykinin,
maximum concentrations were detected only after a delay of 15
minutes. Increased bradykinin concentrations before passage of
the dialyzer were also shown by Verresen et al in patients with
anaphylactoid reactions with and without intake of ACE inhibi-
tors [11]. In contrast, another study performed with patients under
pre-treatment with ACE inhibitors and hemodialysis with AN69
dialyzers demonstrated normal bradykinin concentrations in the
arterial line and only slightly increased concentrations in the
venous line of the extracorporeal circuit. Interestingly, none of
these patients had any anaphylactoid reactions [28]. Taken to-
gether, it could be speculated that bradykinin detection in samples
drawn from the arterial line of the extracorporeal circuit repre-
sents approximately systemic arterial concentrations and may be
extrapolated to the observed anaphylactoid reactions.
Since kinins would be inactivated during first passage of the
pulmonary circulation, high bradykinin concentrations in blood
after passage through the dialyzer do not have any predictable
value on arterial bradykinin levels [29]. Furthermore, it is known
that anaphylactoid reactions in the form of a significant decrease
in systemic blood pressure occur when physiological kinin con-
centrations increase about five- to tenfold in the arterial branch of
the circulation [30, 31]. Therefore, we investigated bradykinin
levels in blood samples drawn directly via a small catheter from
the carotid artery. The puncture and insertion of this catheter in
non-anesthetized sheep was extremely difficult and exhausting for
the animals, so we had to limit this procedure to only two sheep
of group AN/0 and group AN/20 in which anaphylactoid reactions
had been expected. Arterial bradykinin concentrations in group
AN/0 increased five minutes after initiation of hemodialysis
2.5-fold, and were accompanied by a slight hypotension and
tachycardia, suggesting a minor anaphylactoid reaction due to
excessive bradykinin generation exceeding the inactivation capac-
ity of the pulmonary circuit despite absent ACE inhibition.
Arterial bradykinin concentrations of group AN/20 were fourfold
increased at five minutes, at a time when severe anaphylactoid
reactions in the form of collapse occurred. This observation
strongly supports that bradykinin is the mediator of the anaphy-
lactoid reactions.
Effect of the bradykinin B2-receptor antagonist icatibant
Icatibant (Hoe 140) is known as a potent and long-acting
bradykinin antagonist. It prevents bradykinin-induced hypoten-
sion and bronchoconstriction in different in vivo models and in
humans [12, 32, 33]. Futhermore, icatibant has been successfully
applied as an antidote for anaphylactoid reactions during dextran
sulfate LDL apheresis in a patient under ACE inhibition [13].
This led us to use icatibant in one group of animals pretreated
with 30 mg/day enalapril and hemodialyzed with AN69 (group
AN/BA) to prove bradykinin as the mediator of the anaphylactoid
reactions. After application of icatibant before hemodialysis, we
could observe an increase of blood pressure and heart rate and a
marked reduction of tachypnoea. During hemodialysis neither
hypotension, tachycardia, nor collapse occurred, and the ventila-
tion rate fell continuously despite high pre- and post-dialyzer
bradykinin levels that were comparable to those of group AN/30,
in which the most severe anaphylactoid reactions had been noted.
These results provide evidence that bradykinin is the mediator of
anaphylactoid reactions during hemodialysis with the AN69 mem-
brane.
However, the application of icatibant was not without adverse
effects that persisted for hours even after termination of dialysis
due to the extended duration of icatibant action. In every case
these adverse effects appeared before the start of dialysis and
corresponded to symptoms of an intestinal action of bradykinin.
These symptoms were similar to adverse effects of Icatibant
observed during a tolerability testing in dogs and were attributed
to a residual bradykinin B2-receptor agonistic activity [12, 34].
Since the exact dose of icatibant necessary to prevent bradykinin-
induced reactions in sheep was not known, based on recent in vivo
studies we decided to use 0.1 mg/kg. Most probably, lower
icatibant doses would have been better tolerated but the observed
adverse effects were of minor importance for our examinations, so
we were not motivated to alter the dose during the study.
The increase of blood pressure and heart rate after application
of icatibant before dialysis had been most probably a reaction of
the animals due to the observed intestinal symptoms. On the other
hand, a contracting effect of icatibant on the endothelium-free
femoral artery of sheep is known [35]. Therefore, a partial
agonistic effect of icatibant on arterial vessels cannot be excluded
and may have been involved in the pre-dialytic blood pressure
increase and prevention of hypotension after the start of dialysis.
In group AN/30, the hypotension after the beginning of dialysis
was extreme. Since we could not observe even a slight decrease of
blood pressure during dialysis in group AN/BA, the absence of
hypotension can only be due to the antagonistic effect of icatibant
on the endothelium-derived vasodepressive action of bradykinin.
Angiotensin converting enzyme inhibitor dose and
anaphylactoid reactions
To verify the effect of different kininase II inhibition (ACE
activity) on anaphylactoid reactions and contact activation in our
study, hemodialysis with AN69 was performed at different doses
of enalapril. Compared to humans, ACE activity in the group of
sheep without enalapril (group AN/0) was in the normal range
[36]. Administration of enalapril led to a significant dose-depen-
dent reduction of ACE activity. Although daily administration of
10 mg enalapril resulted in an already therapeutic reduction of
ACE activity, increasing the doses (20 and 30 mg/day enalapril)
intensified ACE inhibition.
There seems to be a direct dependency between the enalapril
dose and ACE activity and the severity of anaphylactoid reactions
in hemodialysis with the AN69 membrane. While hemodialysis
without ACE inhibition was nearly uneventful, clinically overt
anaphylactoid reactions could be observed even with as low as 10
mg enalapril. With increasing enalapril doses anaphylactoid reac-
tions became more frequent and severe; with 30 mg enalapril
(group AN/30) all sheep suffered from anaphylactoid reactions.
Probably due to a rapid down-regulation of the bradykinin
B2-receptor through an excess of bradykinin and the potent
compensatory action of the sympathetic nervous system, all sheep
recovered after a few minutes without the need of intervention
and despite continuation of the experiment [37].
A comparison of the enalapril-treated groups did not show a
direct correlation between the dose of enalapril and levels of
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bradykinin. This discrepancy may be explained by the lack of
linearity between the dose of enalapril and ACE inhibition. A
dose of 10 mg enalapril results in ACE inhibition in the thera-
peutic range, while a further increase of the enalapril dose leads
to only a slight additional reduction of ACE activity. This pro-
duces an inadequate increase of bradykinin generation, which is
massive even without ACE inhibition. Furthermore, systemic
bradykinin accumulation may not be the only reason for the
severity of anaphylactoid reactions, since bradykinin levels after
10 mg of enalapril are probably sufficient to provoke more severe
anaphylactoid reactions than observed. Due to ACE inhibition,
the potent counter-regulatory action of angiotensin II is dimin-
ished [38]. This effect adds to the severity of the anaphylactoid
reactions and may explain their dose-dependency on enalapril.
Furthermore, it has been shown that ACE inhibition increases
circulating plasma levels of vasodilators other than bradykinin,
such as prostaglandin E2 (PGE2) and substance P, which could
aggravate hypotension during anaphylactoid reactions [39].
PAN-membrane type and anaphylactoid reactions
In vitro experiments by Lemke and Fink revealed that in
addition to the AN69 membrane the PAN DX membrane also
generates bradykinin in remarkably high amounts [8]. In our study
we could confirm the bradykinin generating property of the PAN
DX membrane in vivo. The kinetics of bradykinin concentrations
during hemodialysis with the PAN DX membrane were compa-
rable to AN69, but the extent of bradykinin levels was less
pronounced, resulting in only minor anaphylactoid reactions after
pretreatment with 20 mg enalapril. This contact activation of PAN
DX could be attributed also to a negatively charged membrane
surface and, since this negative charge may be reduced compared
to AN69, the release of bradykinin is reduced [8]. In fact, negative
surface charge was shown to increase in the sequence SPAN ,
PAN DX , AN69 when these membranes were compared in a
measurement of the zeta-potential between pH 3 to 10 (Werner
C, Tulke A, Lemke HD; manuscript in preparation).
Our study shows that hemodialysis with the AN69 and PAN DX
membranes causes significant contact activation, as indicated by
the generation of bradykinin and the consumption of the contact
system components prekallikrein and high molecular weight
kininogen during the first 15 minutes of dialysis. Between 15 and
60 minutes of dialysis prekallikrein and high molecular weight
kininogen levels remained nearly unchanged, indicating a reduc-
tion of contact activation due to coating of the membrane surface.
While the concentrations of prekallikrein and high molecular
weight kininogen during hemodialysis with AN69 and PAN DX
were nearly similar and bradykinin levels were much higher during
treatment with AN69, it is tempting to speculate that, in contrast
to AN69, the PAN DX membrane is capable of adsorbing high
amounts of bradykinin.
Several in vitro and in vivo studies have shown that the
uncharged polyacrylonitrile membrane SPAN does not generate
bradykinin [10, 40, 41]. Furthermore, hemodialysis of ACE inhib-
ited patients and sheep with this membrane did not provoke
anaphylactoid reactions [10, 41]. Therefore, in our experimental
setting SPAN was used as a control membrane only in enalapril
pretreated animals. All experiments with the SPAN membrane
were clinically uneventful and without changes of bradykinin
concentration. Since there was no alteration of prekallikrein and
high molecular weight kininogen levels, a contact activation
combined with a possible adsorption of bradykinin by SPAN can
be exluded.
Other possible mechanisms of anaphylactoid reactions
Recently, an influence of the calcium composition of the
dialysate on anaphylactoid reactions was suggested. Low dialysate
calcium concentrations (1.25 mmol/liter) were associated with
anaphylactoid reactions in patients on ACE inhibitor therapy and
hemodialysis with the AN69 membrane, whereas changing the
calcium concentration to 1.75 mmol/liter resulted in symptom-
free dialysis in previously symptomatic patients implicating a
possible, direct inhibitory effect of calcium on bradykinin activity
[24]. To exclude the influence of low dialysate calcium concentra-
tions in our experimental setting, a dialysate calcium concentra-
tion of 1.75 mmol/liter, able to prevent anaphylactoid reactions in
human hemodialysis patients, was chosen.
Furthermore, we could exclude a suggested effect of histamine
release on the observed anaphylactoid reactions since histamine
levels remained unaltered during all experiments [25], thereby
confirming the results of in vitro studies and of our previous
animal study [9, 10].
To avoid early hypovolemic effects that could interfere with
bradykinin-mediated anaphylactoid reactions, the priming fluid of
the extracorporeal circuit was administered to the sheep with the
beginning of dialysis. In fact, this procedure prevented blood
pressure alterations as seen in the control group (group SP/20) in
which no bradykinin was released. At the onset of anaphylactoid
reactions in all other groups only about 50 ml of fluid were
withdrawn, a volume unlikely to evoke hypotension. However,
apart from the amount of blood samples taken during the
experiments, the infusion of the priming fluid could have contrib-
uted to the slight reduction of the hemoglobin concentrations and
the platelet counts at the end of dialysis.
Conclusion
Our animal model of hemodialysis with sheep proved to be
suitable for the testing of contact activation. Compared to human
data this species seems to be extraordinarily sensitive to contact
activation with a vigorous release of bradykinin [10, 11, 27, 28].
The results of this study confirm in vitro and in vivo studies that
anaphylactoid reactions during hemodialysis with AN69 mem-
branes are mediated by bradykinin, since they can be prevented by
the bradykinin B2-receptor antagonist icatibant (Hoe 140). The
severity of these anaphylactoid reactions does not depend on the
maximum of bradykinin levels generated by the membrane, but on
the dose of ACE inhibitor and the subsequent ACE activity. The
PAN DX membrane is also capable of activating the contact
system and to release bradykinin although to a lower extent.
Hemodialysis with the SPAN membrane is not associated with any
contact activation.
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